Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III
   trial in intermediate-risk (pN1) early breast cancer: efficacy and
   predictive value of Ki67 expression (vol 25, pg 1551, 2014)

Title:: Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014)
Document type:: Correction
Author(s):: Nitz, U.; Gluz, O.; Huober, J.; Kreipe, H. H.; Kates, R. E.; Hartmann, A.; Erber, R.; Moustafa, Z.; Scholz, M.; Lisboa, B.; Mohrmann, S.; Moebus, V.; Augustin, D.; Hoffmann, G.; Weiss, E.; Boehmer, S.; Kreienberg, R.; du Bois, A.; Sattler, D.; Thomssen, C.; Kiechle, M.; Jaenicke, F.; Wallwiener, D.; Harbeck, N.; Kuhn, W.
Journal title abbreviation:: Ann Oncol
Year:: 2017
Journal volume:: 28
Journal issue:: 11
Pages contribution:: 2899-2899
Language:: eng
Fulltext / DOI:: doi:10.1093/annonc/mdw349
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/27634692
Print-ISSN:: 0923-7534
TUM Institution:: Frauenklinik und Poliklinik
BibTeX

Occurrences: